| Identification | Back Directory | [Name]
Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- | [CAS]
2355377-13-6 | [Synonyms]
DDO-5936
Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- | [Molecular Formula]
C25H29N5O4S | [MDL Number]
MFCD33398564 | [MOL File]
2355377-13-6.mol | [Molecular Weight]
495.59 |
| Chemical Properties | Back Directory | [Boiling point ]
752.5±70.0 °C(Predicted) | [density ]
1.361±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Acetonitrile: Slightly Soluble: 0.1-1 mg/ml
Chloroform: Slightly Soluble: 0.1-1 mg/ml
DMSO: Sparingly Soluble: 1-10 mg/ml | [form ]
Solid | [pka]
3.12±0.10(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1]. | [Biological Activity]
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1].
DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47[1].
DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group[1].DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency[1]. | [in vivo]
DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group[1].
DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency[1]. | Animal Model: | Mice[1] | | Dosage: | 0~80 mg/kg | | Administration: | P.o. | | Result: | Showed a moderate effect at the high dose group.
|
| [References]
[1]. Wang L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2020;63(3):1281-1297. |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|